Brief: Ose Immunotherapeutics Announces First Clinical Results For BI 770371
23/10/2023 17:07
Oct 23 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* ANNOUNCES FIRST CLINICAL RESULTS FOR BI 770371, A NOVEL
ANTI-SIRPΑ MONOCLONAL ANTIBODY
* NOVEL ANTAGONIST ANTI-SIRPΑ MONOCLONAL ANTIBODY (MAB)
TARGETING
BOTH V1 AND V2 SIRPΑ ALLELES MAKES SIRPΑ ANTAGONISTS AN OPTION
FOR MORE CANCER PATIENTS.
Source text for Eikon: ID:nBw2gQ51da
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO